Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.67 |
| ▸ | IGF1R | P08069 | 16/20 | 0.66 |
| ▸ | CDK2 | P24941 | 6/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CDK8 | P49336 | 1/20 | 0.64 |
| ▸ | CDK7 | P50613 | 1/20 | 0.64 |
| ▸ | CDK9 | P50750 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349646 | 1.00 | EGFR (0.67) | EGFRIGF1RCDK2KCNH2CYP3A4 | |
| SCHEMBL2346628 | 1.00 | EGFR (0.67) | EGFRIGF1RCDK2KCNH2CYP3A4 | |
| SCHEMBL2344345 | 0.93 | IGF1R (0.65) | EGFRIGF1RCDK2KCNH2CYP3A4 | |
| SCHEMBL2342901 | 0.93 | IGF1R (0.65) | EGFRIGF1RCDK2KCNH2CYP3A4 | |
| SCHEMBL2345514 | 0.92 | IGF1R (0.60) | EGFRIGF1RCDK2KCNH2CYP3A4 | |
| SCHEMBL2352771 | 0.92 | IGF1R (0.60) | EGFRIGF1RCDK2KCNH2CYP3A4 | |
| SCHEMBL2349062 | 0.90 | IGF1R (0.66) | EGFRIGF1RCDK2KCNH2 | |
| SCHEMBL2361496 | 0.89 | IGF1R (0.84) | EGFRIGF1RCDK2KCNH2CYP3A4 | |
| SCHEMBL3378394 | 0.89 | IGF1R (0.84) | EGFRIGF1RCDK2KCNH2CYP3A4 | |
| SCHEMBL2365358 | 0.89 | IGF1R (0.84) | EGFRIGF1RCDK2KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | claimed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | EGFR 2481/4885IGF1R 4384/4885CDK2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.